In conclusion, this analysis revealed that the use of Oncomine DxTT in patients with advanced/recurrent nonsquamous NSCLC is not cost-effective in Japan compared with the three single-gene tests (EGFR/ALK/ROS1). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.